Study ADX-324-302 is an extension study for participants who complete the Phase 3 ADX-324-301 trial. The extension study will provide information about the safety and efficacy of additional dosing of ADX-324 in participants with Type I and Type II hereditary angioedema (HAE). The study will also include pharmacodynamic (PD), pharmacokinetic (PK), and health-related quality of life (HRQoL) measurements.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
90
siRNA duplex oligonucleotide
siRNA duplex oligonucleotide
ADARx Clinical Site
Litchfield Park, Arizona, United States
NOT_YET_RECRUITINGADARx Clinical Site
Little Rock, Arkansas, United States
NOT_YET_RECRUITINGADARx Clinical Site
San Diego, California, United States
NOT_YET_RECRUITINGADARx Clinical Site
Walnut Creek, California, United States
NOT_YET_RECRUITINGSafety of ADX-324 in Participants with HAE
Incidence and severity of treatment-emergent adverse events
Time frame: Month 36
Efficacy of ADX-324 in Preventing HAE Attacks
Number of Investigator-confirmed HAE attacks per month
Time frame: Month 36
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
ADARx Clinical Site
Orlando, Florida, United States
NOT_YET_RECRUITINGADARx Clinical Site
Chevy Chase, Maryland, United States
NOT_YET_RECRUITINGADARx Clinical Site
Wheaton, Maryland, United States
NOT_YET_RECRUITINGADARx Clinical Site
Detroit, Michigan, United States
NOT_YET_RECRUITINGADARx Clinical Site
St Louis, Missouri, United States
NOT_YET_RECRUITINGADARx Clinical Site
Las Vegas, Nevada, United States
RECRUITING...and 38 more locations